Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 374 of 5804
-
New triple-drug attack shows promise for hard-to-treat ovarian cancer
Disease control Recruiting nowOvarian cancer is one of the most common gynecologic malignancies, with considerable histologic heterogeneity; more than 90 % of cases are epithelial ovarian cancers. Because no reliable tools exist for early detection, approximately 70 % of patients are diagnosed at an advanced …
Phase: PHASE2 • Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
AI reads tumor slides to forecast cancer spread
Knowledge-focused Recruiting nowThe goal of this observational study is to develop and validate an artificial intelligence (AI) model for predicting the risk of distant metastasis in patients with primary breast cancer. The main question it aims to answer is: Can a multimodal AI model, trained on routinely ava…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells take on deadly brain tumor
Disease control Not yet recruitingA Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
Phase: EARLY_PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New vaccine aims to shield infants from deadly pneumonia
⭐️ VACCINE ⭐️ Recruiting nowThis is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a…
Phase: PHASE3 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:09 UTC
-
Tailored therapy shows promise in cutting suicide risk
Symptom relief Recruiting nowIndividuals at high-risk of suicide vary substantially from one another. Over time, risk factors for suicide may change within the same individual. Despite these differences, most treatments for suicidal thoughts assume that the same intervention works equally well for all indivi…
Phase: NA • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Liver cancer hope: Immuno-Chemo combo targets tough tumors
Disease control Recruiting nowLiver cancer is a highly lethal malignancy and has become increasingly important in western countries. The management of liver cancer is complex. In advanced disease, two combinations of immunotherapies are recommanded as first line (atezolizumab-bevacizumab or durvalumab-tremeli…
Phase: PHASE2, PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Scientists combine CAR t therapy and bone marrow transplant to attack tough blood cancers
Disease control Recruiting nowBackground: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone. These cancers may be treated and potentially cured in 2 ways: (1) Bone marrow transplant (allogeneic hematopoietic cell transplantatio…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Which Pre-Surgery combo works best for HER2+ breast cancer? new trial aims to find out
Disease control Recruiting nowThis is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Pulsed proton beams aim to tame tough pancreatic tumors
Disease control Recruiting nowPancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection. A substantial proportion of patients present with locally advanced, unresectable disease at the time of diagno…
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for painful hand and foot pustules: phase 3 trial launches
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can pressurized oxygen beat Flesh-Eating bacteria?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if hyperbaric oxygen is beneficial in treating necrotizing infections and decreasing rates of morbidity and mortality. This study therefore has two aims: 1. Determine if hyperbaric oxygen improve morbidity and mortality compared to sta…
Phase: NA • Sponsor: Corewell Health West • Aim: Disease control
Last updated Jun 26, 2026 16:39 UTC
-
Major trial questions need for extra surgery in melanoma patients
Disease control Recruiting nowThis multicenter, phase III randomized controlled trial evaluates whether omitting re-excision after complete primary excision of cutaneous melanoma affects patient outcomes. A total of 1,749 patients with pT1b-pT4b cutaneous melanoma without evidence of metastases will be random…
Phase: PHASE3 • Sponsor: Marieke Goodijk • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Brain stimulation trial aims to lift teen depression in hospital
Symptom relief Recruiting nowEvaluate the feasibility, safety, and preliminary efficacy of deep Transcranial Magnetic Stimulation (dTMS) as an adjunctive treatment for adolescents hospitalized with major depressive disorder (MDD).
Phase: NA • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New hope for ovarian cancer: targeted drug combo enters Mid-Stage trial
Disease control Recruiting nowOvarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), o…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New pill could ease painful skin lumps for those failed by antibiotics
Disease control Recruiting nowThe purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps. This study is seeking participants who: * hav…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New cell therapy aims to tame tough autoimmune diseases
Disease control Recruiting nowThis study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc. Aproximately 18 patients aged 18-65 will receive a single infusion o…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New immune therapy targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.
Phase: PHASE1, PHASE2 • Sponsor: CuraCell TX AB • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy shows promise for hard-to-treat breast cancer
Disease control Recruiting nowThis is a Phase II single-arm study designed to evaluate the efficacy and safety of Sac-TMT + KL-A167 in 35 patients with PD-L1+, HR+/HER2- metastatic breast cancer who previously treated with CDK4/6 inhibitor. The primary endpoint is the 6-month PFS rate. Treatment will continue…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and …
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New cream could help kids with vitiligo regain skin color
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC